Drugmakers ramp up efforts to develop cure for Ebola virus

08/13/2014 | BioPharmaReporter.com

Several biopharmaceutical firms are working to develop antibody drugs for the Ebola virus as the death toll from the outbreak continues to increase. Tekmira Pharmaceuticals and Sarepta Therapeutics are developing RNAi-based therapies, while GlaxoSmithKline is working on a vaccine. But among all experimental drugs for Ebola, Mapp Biopharmaceutical's monoclonal antibody cocktail ZMapp appears to be the unapproved treatment of choice so far, and has already been used to treat infected patients. The vast majority of the experimental treatments, however, are unlikely to be ready for at least a year.

View Full Article in:

BioPharmaReporter.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations